Association of acyl carnitines and mortality in out-of-hospital-cardiac-arrest patients: Results of a prospective observational study.


Journal

Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642

Informations de publication

Date de publication:
08 2020
Historique:
received: 18 01 2020
revised: 23 03 2020
accepted: 23 03 2020
pubmed: 13 4 2020
medline: 25 5 2021
entrez: 13 4 2020
Statut: ppublish

Résumé

Out-of-hospital cardiac arrest (OHCA) is a leading cause of mortality, yet the prediction of its outcome remains challenging. Serum Acyl Carnitines (ACs), a biomarker of beta-oxidation, have been associated with cardiovascular events. We evaluated the association of different AC species with mortality and neurological outcome in a cohort of OHCA patients. We consecutively included OHCA patients in this prospective observational study upon admission to the intensive care unit. We studied the association of thirty-nine different ACs measured at admission and 30-day mortality (primary endpoint), as well as neurological outcome at hospital discharge (secondary endpoint) using the Cerebral Performance Category scale. Multivariate models were adjusted for age, gender, comorbidities and shock markers. Of 281 included patients, 137 (48.8%) died within 30 days and of the 144 survivors (51.2%), 15 (10.4%) had poor neurological outcome. While several ACs were associated with mortality, AC C2 had the highest prognostic value for mortality (fully-adjusted odds ratio 4.85 (95%CI 1.8 to 13.06, p < .01), area under curve (AUC) 0.65) and neurological outcome (fully-adjusted odds ratio 3.96 (95%CI 1.47 to 10.66, p < .01), AUC 0.63). ACs are interesting surrogate biomarkers that are associated with mortality and poor neurological outcome in patients after OHCA and may help to improve the understanding of pathophysiological mechanisms and risk stratification.

Identifiants

pubmed: 32279017
pii: S0883-9441(20)30042-3
doi: 10.1016/j.jcrc.2020.03.009
pii:
doi:

Substances chimiques

Biomarkers 0
Carnitine S7UI8SM58A

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-26

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The corresponding author states on behalf of all authors that there was no conflict of interest for this trial.

Auteurs

Madlaina Widmer (M)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland.

Emanuel B Thommen (EB)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland.

Christoph Becker (C)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland; Faculty of Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland; Emergency Department, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Katharina Beck (K)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland.

Alessia M Vincent (AM)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland.

Sebastian Perrig (S)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland.

Annalena Keller (A)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland.

Luca Bernasconi (L)

Institute of Laboratory Medicine, Kantonsspital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.

Peter Neyer (P)

Institute of Laboratory Medicine, Kantonsspital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.

Stephan Marsch (S)

Faculty of Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland; Departement of Intensive Care, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Hans Pargger (H)

Faculty of Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland; Departement of Intensive Care, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Raoul Sutter (R)

Faculty of Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland; Departement of Intensive Care, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Kai Tisljar (K)

Departement of Intensive Care, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Sabina Hunziker (S)

Department of Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031 Basel, Switzerland; Faculty of Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland; Departement of Intensive Care, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. Electronic address: Sabina.hunziker@usb.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH